RS
REGN icon

R Squared’s Regeneron Pharmaceuticals REGN Stock Holding History

R Squared’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$263K – 679
2025
Q2 		$263K Hold
500
– – 0.14% 249
2025
Q1 		$317K Sell
500
-110
-18% -$75.7K 0.34% 119
2024
Q4 		$435K Buy
+610
New +$512K 0.42% 35

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

R Squared's REGN Position: Q3 2025 in Review

R Squared sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 500 shares — an estimated $263K sold.

R Squared first reported a position in REGN in Q4 2024 and held it in 3 quarters. The position peaked at $435K in Q4 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • R Squared reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • R Squared sold 500 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $263K.
  • R Squared first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • R Squared's Regeneron Pharmaceuticals position peaked at $435K in Q4 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.